This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

CBT for Patients With Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders

This study has been completed.
Fonds NutsOhra
Information provided by (Responsible Party):
Arkin Identifier:
First received: September 8, 2011
Last updated: January 13, 2017
Last verified: January 2017
The purpose of this study is to determine if cognitive behavioral therapy is effective in treating ADHD symptoms in patients with substance use disorders and comorbid ADHD.

Condition Intervention
Attention Deficit Hyperactivity Disorder Substance Use Disorders Behavioral: cognitive behavioral therapy for treating ADHD symptoms

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Investigating the Efficacy of Cognitive Behavioral Therapy in Patients With Substance Use Disorder and Comorbid ADHD. A Randomized Controlled Trial With Cognitive Behavioral Therapy

Resource links provided by NLM:

Further study details as provided by Arkin:

Primary Outcome Measures:
  • self reported ADHD symptoms [ Time Frame: 6 months ]
    Dutch self report list of ADHD symptoms by Kooij and Buitelaar

Secondary Outcome Measures:
  • Time Line Follow Back method [ Time Frame: 6 months ]
    self-reported alcohol and drug use

  • Beck depression inventory [ Time Frame: 6 months ]
    self reported depression symptoms

  • Beck Anxiety Inventory [ Time Frame: 6 months ]
    Self reported anxiety symptoms

  • EQ-5 [ Time Frame: 6 months ]
    Self reported quality of living

  • TIC-P [ Time Frame: 6 months ]
    health care consumption and production loss in relation to mental health problems

  • Stroop task [ Time Frame: 6 months ]
    neuropsychological measure

  • Tower of London task [ Time Frame: 6 months ]
    neuropsychological task

  • BART task [ Time Frame: 6 months ]
    neuropsychological task on risk taking behavior

  • urine checks [ Time Frame: 6 months ]
    urine checks on drug use

Enrollment: 184
Study Start Date: August 2011
Study Completion Date: December 2016
Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: standard addiction treatment
10 sessions of standard addiction treatment. No ADHD treatment.
Experimental: addiction treatment and ADHD treatment
10 sessions cognitive behavioral therapy on addiction treatment combined with 5 sessions on ADHD treatment.
Behavioral: cognitive behavioral therapy for treating ADHD symptoms
5 sessions of one hour CBT for treating ADHD symptoms by a trained health care worker

Detailed Description:
Attention Deficit Hyperactivity Disorder(ADHD) is an important comorbid condition in patients with substance use disorders (SUD). The prevalence of ADHD in patients with SUD is estimated 23%, and ADHD is associated with an untoward prognosis of SUD. However, adequate treatment programs for patients with ADHD and SUD are not available. Results of medication trials for patients with ADHD and SUD are disappointing, and cognitive behavioral therapy (CBT) has not yet been investigated in this population. In patients with ADHD without comorbid SUD, the results of CBT in randomized trials are positive. The purpose of this study is to investigate if CBT is effective in treating ADHD symptoms in patients with ADHD and SUD.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • substance use disorder
  • ADHD
  • able to comply with study activities

Exclusion Criteria:

  • severe neurological or psychiatric diseases (for example Parkinson, dementia, psychosis, bipolar depression) which require medication
  • unable to read or write Dutch language
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01431235

Amsterdam, Netherlands
Sponsors and Collaborators
Fonds NutsOhra
Principal Investigator: Robert Schoevers, MD, PhD University Medical Center Groningen
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Arkin Identifier: NCT01431235     History of Changes
Other Study ID Numbers: 10-130
Study First Received: September 8, 2011
Last Updated: January 13, 2017

Keywords provided by Arkin:
cognitive behavioral therapy

Additional relevant MeSH terms:
Attention Deficit Disorder with Hyperactivity
Substance-Related Disorders
Pathologic Processes
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders
Mental Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Chemically-Induced Disorders processed this record on August 18, 2017